Today, Oxford Cancer Biomarkers are pleased to announce the publication of the ToxNav® clinical validation study in the journal Cancers. This milestone represents a significant step forward for OCB and the ToxNav® brand.
ToxNav® is OCB’s flag ship precision oncology product and is being offered routinely to patients in several NHS Trusts and private hospital groups in the UK. The ToxNav® assay identifies patients carrying genetic variants associated with the risk of severe side effects ahead of treatment with fluoropyrimidine based chemotherapy. This allows patients and clinicians to make informed treatment decisions on an individual basis. ToxNav® is the second product developed by OCB to hold a CE mark.
Fluoropyrimidines are first line treatment in patients with colorectal cancer. These drugs are also widely used in other cancers including breast cancer and a range of gastrointestinal malignancies.
ToxNav® is the most comprehensive DPYD test available. ToxNav® screens for 20 different variants, including rare variants and variants observed at increased frequency in ethnic populations. In addition to variants associated with severe side effects that may lead to hospitalisation, ToxNav® also includes variants linked to an increased risk of hand-foot syndrome (HFS). The publication of the ToxNav® validation data goes one step further towards widening access to all patients in the UK who are about to commence 5-FU or capecitabine chemotherapy.